Blood cyclosporine level soon after kidney transplantation is a major determinant of rejection: Insights from the mycophenolate steroid-sparing trial

E. Gotti, N. Perico, F. Gaspari, D. Cattaneo, M. D. Lesti, P. Ruggenenti, G. Segoloni, M. Salvadori, P. Rigotti, U. Valente, D. Donati, S. Sandrini, S. Federico, V. Sparacino, G. Mourad, J. L. Bosmans, B. D. Dimitrov, B. E. Iordache, G. Remuzzi

Research output: Contribution to journalArticle

Abstract

Target organs express antigens directly recognized by antigen-specific T cells, thereby precipitating rejection. When early T-cell activation is inhibited, there is a low risk of rejection. We sought to determine the predictive values of serial posttransplant blood cyclosporine trough (C 0) concentrations to minimize the risk for a first rejection episode compared with 2-hour postdose (C2) drug concentrations. The final aim of the study was to identify a concentration range for the best predictive pharmacokinetic parameter that should be targeted to reduce the risk of rejection. This possibility was explored in 334 de novo kidney transplant recipients who participated in the prospective, multicenter Mycophenolate Steroid-Sparing Trial. Among measurements performed during the first 6 months postsurgery, cyclosporine C0 levels measured early after transplantation were the strongest predictor of acute graft rejection. Levels within 300 to 440 ng/mL were associated with the lowest risk of rejection, while patients with levels lower than 300 ng/mL showed a more than double risk. Cyclosporine trough values predicted allograft rejection with an accuracy of 74%, while C2 levels had no predictive value. These findings underline the need to target cyclosporine therapy early posttransplant to modulate T-cell activation.

Original languageEnglish
Pages (from-to)2037-2040
Number of pages4
JournalTransplantation Proceedings
Volume37
Issue number5
DOIs
Publication statusPublished - Jun 2005

Fingerprint

Kidney Transplantation
Cyclosporine
Steroids
T-Lymphocytes
Antigens
Graft Rejection
Allografts
Pharmacokinetics
Transplantation
Kidney
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Blood cyclosporine level soon after kidney transplantation is a major determinant of rejection : Insights from the mycophenolate steroid-sparing trial. / Gotti, E.; Perico, N.; Gaspari, F.; Cattaneo, D.; Lesti, M. D.; Ruggenenti, P.; Segoloni, G.; Salvadori, M.; Rigotti, P.; Valente, U.; Donati, D.; Sandrini, S.; Federico, S.; Sparacino, V.; Mourad, G.; Bosmans, J. L.; Dimitrov, B. D.; Iordache, B. E.; Remuzzi, G.

In: Transplantation Proceedings, Vol. 37, No. 5, 06.2005, p. 2037-2040.

Research output: Contribution to journalArticle

Gotti, E, Perico, N, Gaspari, F, Cattaneo, D, Lesti, MD, Ruggenenti, P, Segoloni, G, Salvadori, M, Rigotti, P, Valente, U, Donati, D, Sandrini, S, Federico, S, Sparacino, V, Mourad, G, Bosmans, JL, Dimitrov, BD, Iordache, BE & Remuzzi, G 2005, 'Blood cyclosporine level soon after kidney transplantation is a major determinant of rejection: Insights from the mycophenolate steroid-sparing trial', Transplantation Proceedings, vol. 37, no. 5, pp. 2037-2040. https://doi.org/10.1016/j.transproceed.2005.03.096
Gotti, E. ; Perico, N. ; Gaspari, F. ; Cattaneo, D. ; Lesti, M. D. ; Ruggenenti, P. ; Segoloni, G. ; Salvadori, M. ; Rigotti, P. ; Valente, U. ; Donati, D. ; Sandrini, S. ; Federico, S. ; Sparacino, V. ; Mourad, G. ; Bosmans, J. L. ; Dimitrov, B. D. ; Iordache, B. E. ; Remuzzi, G. / Blood cyclosporine level soon after kidney transplantation is a major determinant of rejection : Insights from the mycophenolate steroid-sparing trial. In: Transplantation Proceedings. 2005 ; Vol. 37, No. 5. pp. 2037-2040.
@article{3bc811dd3a11440f8354fd87531e77e7,
title = "Blood cyclosporine level soon after kidney transplantation is a major determinant of rejection: Insights from the mycophenolate steroid-sparing trial",
abstract = "Target organs express antigens directly recognized by antigen-specific T cells, thereby precipitating rejection. When early T-cell activation is inhibited, there is a low risk of rejection. We sought to determine the predictive values of serial posttransplant blood cyclosporine trough (C 0) concentrations to minimize the risk for a first rejection episode compared with 2-hour postdose (C2) drug concentrations. The final aim of the study was to identify a concentration range for the best predictive pharmacokinetic parameter that should be targeted to reduce the risk of rejection. This possibility was explored in 334 de novo kidney transplant recipients who participated in the prospective, multicenter Mycophenolate Steroid-Sparing Trial. Among measurements performed during the first 6 months postsurgery, cyclosporine C0 levels measured early after transplantation were the strongest predictor of acute graft rejection. Levels within 300 to 440 ng/mL were associated with the lowest risk of rejection, while patients with levels lower than 300 ng/mL showed a more than double risk. Cyclosporine trough values predicted allograft rejection with an accuracy of 74{\%}, while C2 levels had no predictive value. These findings underline the need to target cyclosporine therapy early posttransplant to modulate T-cell activation.",
author = "E. Gotti and N. Perico and F. Gaspari and D. Cattaneo and Lesti, {M. D.} and P. Ruggenenti and G. Segoloni and M. Salvadori and P. Rigotti and U. Valente and D. Donati and S. Sandrini and S. Federico and V. Sparacino and G. Mourad and Bosmans, {J. L.} and Dimitrov, {B. D.} and Iordache, {B. E.} and G. Remuzzi",
year = "2005",
month = "6",
doi = "10.1016/j.transproceed.2005.03.096",
language = "English",
volume = "37",
pages = "2037--2040",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Blood cyclosporine level soon after kidney transplantation is a major determinant of rejection

T2 - Insights from the mycophenolate steroid-sparing trial

AU - Gotti, E.

AU - Perico, N.

AU - Gaspari, F.

AU - Cattaneo, D.

AU - Lesti, M. D.

AU - Ruggenenti, P.

AU - Segoloni, G.

AU - Salvadori, M.

AU - Rigotti, P.

AU - Valente, U.

AU - Donati, D.

AU - Sandrini, S.

AU - Federico, S.

AU - Sparacino, V.

AU - Mourad, G.

AU - Bosmans, J. L.

AU - Dimitrov, B. D.

AU - Iordache, B. E.

AU - Remuzzi, G.

PY - 2005/6

Y1 - 2005/6

N2 - Target organs express antigens directly recognized by antigen-specific T cells, thereby precipitating rejection. When early T-cell activation is inhibited, there is a low risk of rejection. We sought to determine the predictive values of serial posttransplant blood cyclosporine trough (C 0) concentrations to minimize the risk for a first rejection episode compared with 2-hour postdose (C2) drug concentrations. The final aim of the study was to identify a concentration range for the best predictive pharmacokinetic parameter that should be targeted to reduce the risk of rejection. This possibility was explored in 334 de novo kidney transplant recipients who participated in the prospective, multicenter Mycophenolate Steroid-Sparing Trial. Among measurements performed during the first 6 months postsurgery, cyclosporine C0 levels measured early after transplantation were the strongest predictor of acute graft rejection. Levels within 300 to 440 ng/mL were associated with the lowest risk of rejection, while patients with levels lower than 300 ng/mL showed a more than double risk. Cyclosporine trough values predicted allograft rejection with an accuracy of 74%, while C2 levels had no predictive value. These findings underline the need to target cyclosporine therapy early posttransplant to modulate T-cell activation.

AB - Target organs express antigens directly recognized by antigen-specific T cells, thereby precipitating rejection. When early T-cell activation is inhibited, there is a low risk of rejection. We sought to determine the predictive values of serial posttransplant blood cyclosporine trough (C 0) concentrations to minimize the risk for a first rejection episode compared with 2-hour postdose (C2) drug concentrations. The final aim of the study was to identify a concentration range for the best predictive pharmacokinetic parameter that should be targeted to reduce the risk of rejection. This possibility was explored in 334 de novo kidney transplant recipients who participated in the prospective, multicenter Mycophenolate Steroid-Sparing Trial. Among measurements performed during the first 6 months postsurgery, cyclosporine C0 levels measured early after transplantation were the strongest predictor of acute graft rejection. Levels within 300 to 440 ng/mL were associated with the lowest risk of rejection, while patients with levels lower than 300 ng/mL showed a more than double risk. Cyclosporine trough values predicted allograft rejection with an accuracy of 74%, while C2 levels had no predictive value. These findings underline the need to target cyclosporine therapy early posttransplant to modulate T-cell activation.

UR - http://www.scopus.com/inward/record.url?scp=21844432663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21844432663&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2005.03.096

DO - 10.1016/j.transproceed.2005.03.096

M3 - Article

C2 - 15964332

AN - SCOPUS:21844432663

VL - 37

SP - 2037

EP - 2040

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 5

ER -